Document is current

Article History

Received: 6 September 2024

Accepted: 28 December 2024

First Online: 27 February 2025

Declarations

:

: LAA has served as an advisory board member or speaker for Novo Nordisk, CSL Behring and Gilead. ME has received personal fees from Pfizer and honoraria from Sanofi. JG is on advisory boards and receives honoraria for talks from Novo Nordisk, AstraZeneca, Roche, BMS, Pfizer, Cincera, Pharmaxis and Boehringer Mannheim. JH has received competitive grant funding from Gilead Sciences and speaker fee and ad board support from Roche and Astra-Zeneca, none relevant to this clinical guideline. JFH has received research grant from Gilead, Bristol-Myer-Squibb, serves as a consultant for Roche, Sysmex, Boehringer Ingelheim, Aligos, and has been a speaker for AbbVie, Gilead, Merck, Sysmex, and Novo Nordisk. WK has received honoraria and served in an advisory role for Gilead, Boehringer-Ingelheim, GSK, Novo Nordisk, Samil, Ildong, LG Chemistry, YUHAN, Hanmi, HK Inoen, Standigm, PharmaKing, KOBIOLABS, Olix Pharma, TSD Life Sciences, Daewoong, QUEST, Therasid Bioscience, Korea United Pharm, and Eisai; has received research funding from GSK, Gilead, Novartis, Pfizer, Roche, Springbank, Altimmune, Ildong, DaeWoong, Dicerna, Celgene, Hanmi, Novo Nordisk, Galmed, Enyo. TK received lecture fees from ASKA Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., AbbVie GK., Eisai Co., Ltd., Novo Nordisk Pharma Ltd., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd., EA Pharma Co., Ltd. and KOBIOLABS; holds stock in KOBIOLABS and Lepidyne; and is the founder of Remedygen Incorporation. SKR is a member of the Advisory Board for Novo Nordisk. The other authors disclose no conflicts. SIS has received honoraria for advisory boards or speaking from Roche, Astra Zeneca, Ipsen, Eisai, Sirtex, BMS, MSD, AbbVie, Gilead Sciences, Norgine, Astellas, Novartis, Pfizer, CSL-Behring, Dr Falk Pharma, Chiesi, Novo Nordisk. WKS received speaker’s fees from Echosens, is an advisory board member and received speaker's fees from Abbott, received research funding from Astrazeneca, Alexion Pharmaceuticals, Boehringer Ingelheim, Pfizer and Ribo Life Science, and is an advisory board member, received speaker’s fees and research funding from Gilead Sciences. VW has provided consultancy services to AbbVie, AstraZeneca, Boehringer Ingelheim, Echosens, Eli Lilly, Gilead Sciences, Intercept, Inventiva, Merck, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, and Visirna; has delivered lectures for Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk, and Unilab; has received research grants from Gilead Sciences; and he is a co-founder of Illuminatio Medical Technology, in which he holds stock. MLY has research support from Abbvie, Abbott Diagnostic, BMS, Gilead, Merck and Roche diagnostics; served as a consultant of Abbott, Abbvie, Abbott Diagnostic, BMS, Gilead, Roche and Roche diagnostics and a speaker of Abbvie, BMS, Eisai, Gilead, Roche and Roche diagnostics. YY has served as a consultant for Zydus, Cymabay, and Novo Nordisk, and as a speaker for Echosens. MHZ has received honoraria for lectures from AstraZeneca, Hisky Medical Technologies and Novo Nordisk, consulting fees from Boehringer Ingelheim. Outside their participation in this work. The other authors disclose no conflicts.

: Not applicable.

Free to read: This content has been made available to all.